Evidence map›Paper›PMID 35768763›Full record

ArticleBMC infectious diseases2022

Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system.

Takuya Ozawa, Ho Namkoong, Risako Takaya, Yusuke Takahashi, Koichi Fukunaga, Yuki Enoki, Kazuaki Taguchi, Junko Kizu, Kazuaki Matsumoto, Naoki Hasegawa

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Comprehensive Management Algorithm forAnnals of the American Thoracic Society · 2025
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Takuya OzawaDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Ho NamkoongDepartment of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan. hounamugun@gmail.com.
Risako TakayaDivision of Practical Pharmacy, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Yusuke TakahashiDivision of Practical Pharmacy, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Koichi FukunagaDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Yuki EnokiDivision of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Kazuaki TaguchiDivision of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Junko KizuDivision of Practical Pharmacy, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Kazuaki MatsumotoDivision of Practical Pharmacy, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Naoki HasegawaDepartment of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
Keio University · JPKeio University Hospital · JP

Funding

Grant-in-Aid for Young Scientists 21K15667Japan Agency for Medical Research and Development 21fk0108621h0001JST PRESTO JPMJPR21R7
6 · The paper itself

Abstract

backgroundIn Japan, Mycobacterium avium complex lung disease (MAC-LD) is the most common in nontuberculous mycobacterial lung disease. Patients often experience adverse events, resulting in the discontinuation of treatment, which causes treatment failure. The JADER (Japanese Adverse Drug Event Report) database is a database of adverse events that allows us to collect real-world data on adverse events. We can collect large-scale data cost-effectively and detect signals of potential adverse events such as reporting odds ratio (ROR) by using spontaneous reporting systems. In this study, we aimed to elucidate the adverse events of clarithromycin (CAM), ethambutol (EB), and rifampicin (RFP) using the JADER database.

methodsWe included cases of MAC-LD between April 2004 and June 2017. We investigated sex, age, and medications that may have caused the adverse events, outcomes, and time of onset. We calculated the safety signal index as the ROR. Time-to-event analysis was performed using the Weibull distribution.

resultsThe total number of adverse events of CAM, EB, and RFP was 2780, with 806 patients. In the overall adverse events, hematologic and lymphatic disorders were the most common adverse events, with 17.3%, followed by eye disorders (16.6%), and hepatobiliary disorders (14.0%). The outcomes were as follows: recovery, 40.0%; remission, 27.1%; non-recovery, 11.2%; and death, 7.1%. Regarding the most common onset time of CAM, EB, and RFP was within 120 days at 40%, 181-300 days at 43.6%, and within 120 days at 88.5%. For CAM, the RORs of infections and infestations, hepatobiliary system disorders, and immune system disorders were 4.13 (95% confidence interval [CI], 2.3-7.44), 2.61 (95% CI, 1.39-4.91), and 2.38 (95% CI, 1.04-5.44). For EB, the ROR of eye disorders was 215.79 (95% CI, 132.62-351.12). For RFP, the RORs of renal and urinary tract disorders and investigations were 7.03 (95% CI, 3.35-14.77) and 6.99 (95% CI, 3.22-15.18). The β value of EB was 2.07 (95% CI, 1.48-2.76), which was classified as a wear-out failure type.

conclusionsFor MAC-LD, the adverse event which has the highest ROR is infections and infestations in CAM, eye disorders in EB, renal and urinary tract disorders in RFP. Adverse events of EB occur after 180 days, whereas the adverse events of CAM and RFP occur early in the course of treatment.

Indexed as

Drug-Related Side Effects and Adverse ReactionsLung DiseasesMycobacterium avium-intracellulare InfectionClarithromycinEthambutolHumansJapanMycobacterium avium ComplexRifampinClarithromycinEthambutolRifampinAdverse eventsClarithromycinEthambutolJapanese Adverse Drug Event Report (JADER)Mycobacterium avium complex (MAC)Reporting odds ratioRifampicinWeibull distribution

Identifiers

PMID35768763
PMCPMC9241207
OpenAlexW4283710721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.